MedTrace Logo

Assessment of Progranulin and FAM19A5 Protein Blood Levels in Metabolic Syndrome

NCT04451616 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2020-08-14

No results posted yet for this study

Summary

The main objective of the study is to assess the serum levels of progranulin and FAM19A5 protein in adults with metabolic syndrome.

Conditions

  • Nutrition Disorders
  • Hypertension
  • Dyslipidemias
  • Glucose Intolerance
  • Glucose Metabolism Disorders
  • Obesity
  • Overweight and Obesity
  • Metabolic Syndrome

Interventions

DIAGNOSTIC_TEST

Blood sample collection

Fasting blood sample will be collected from forearm vein. In the sample the concentration of: progranulin and serum FAM19A5 protein, leptin, VEGF, insulin, neopterin, adropin and selected cytokines, adipokines, myokines and chemokines, total cholesterol, low-density lipoproteins, high-density lipoproteins, triglycerides and glucose will be determined. Whole blood sample will be secured to isolate genetic material, detect and examine progranulin and FAM19A5 genes, and genes associated with the development of metabolic syndrome and with the body's mineral management. Serum mineral analysis will be performed.

DIAGNOSTIC_TEST

Hair sample collection

Hair sample collection will be performed. Hair mineral analysis will be performed.

DIAGNOSTIC_TEST

Urine sample collection

Urine sample collection will be performed. Urine mineral analysis will be performed.

DIAGNOSTIC_TEST

Body composition analysis

Body composition analysis with the use of electric bioimpedance will be performed.

DIAGNOSTIC_TEST

Questionnaires

Dietary and lifestyle interview with the use of dietary and lifestyle questionnaires and dietary diaries will be performed.

DIAGNOSTIC_TEST

Blood pressure, pulse and blood oxygen saturation measurement

Blood pressure, pulse and blood oxygen saturation measurements with the use of non-invasive methods will be performed.

Sponsors & Collaborators

  • Poznan University of Medical Sciences

    lead OTHER

Principal Investigators

  • Damian Skrypnik, MD; PhD · Poznan University of Medical Sciences

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-07-03
Primary Completion
2021-06-01
Completion
2021-06-01

Countries

  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04451616 on ClinicalTrials.gov